Notes on Elafibronor
Iqirvo, as a medication for treating specific liver diseases, requires attention to liver function monitoring, drug interactions, and medication management for special populations. Special attention should be paid to the risk of myopathy, allergic reactions, and adverse reactions such as biliary obstruction, while emphasizing the use during pregnancy and safety assessment during lactation.
1. Liver function monitoring
(1) ALT, AST, ALP, and bilirubin levels should be regularly monitored before and during treatment, once a month for the first 6 months and every 3 months thereafter.
(2) Patients with cirrhosis need to be closely monitored for signs of decompensation, and medication should be discontinued if ascites or hepatic encephalopathy occur.
2. Drug interactions
(1) Prohibiting the use of CYP3A strong inducers (such as rifampicin) in combination may significantly reduce therapeutic efficacy.
(2) When used in combination with CYP3A inhibitors (such as ketoconazole), the dosage should be adjusted and grapefruit products should be avoided.
3. Special adverse reactions
(1) Muscle disease risk: Muscle pain symptoms need to be evaluated at baseline, especially when combined with statins, which may cause rhabdomyolysis.
(2) Allergic reactions: Severe allergies require permanent discontinuation of medication, while mild to moderate reactions require interruption of treatment until symptoms subside.
(3) Biliary obstruction: Patients with complete obstruction should not use it, and treatment should be interrupted when there is suspicion of obstruction.
4. Medication for special populations
(1) Pregnant women: May cause fetal damage, confirm pregnancy status and strictly use contraception before medication.
(2) Breastfeeding period: The impact of medication on infants is unknown. Breastfeeding is prohibited during the treatment period and within 3 weeks after discontinuation of medication.
(3) Elderly: Patients over 75 years old need to strengthen monitoring of adverse reactions.
5. Other precautions
(1) Fracture risk: Regular assessment of bone health is required during treatment, with a 6% higher incidence rate compared to the placebo group.
(2) Cataract screening: Pediatric patients need to undergo ophthalmic examination before and after medication.
Disclaimer：《Notes on Elafibronor》Edited and sorted by Seagull Pharmacy's editors. Please contact us in time if there is any infringement. In addition, the suggestions for drug usage, dosage and disease mentioned in the article are only for medical staff's reference, and can not be used as any basis for medication！